Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Return on Equity: 2019-2021

Historic Return on Equity for Black Diamond Therapeutics (BDTX) over the last 1 years, with Sep 2021 value amounting to -0.44%.

  • Black Diamond Therapeutics' Return on Equity fell 28.00% to -0.44% in Q3 2021 from the same period last year, while for Sep 2021 it was -0.44%, marking a year-over-year decrease of 28.00%. This contributed to the annual value of -0.50% for FY2020, which is 142.00% down from last year.
  • According to the latest figures from Q3 2021, Black Diamond Therapeutics' Return on Equity is -0.44%, which was down 40.80% from -0.31% recorded in Q2 2021.
  • Black Diamond Therapeutics' 5-year Return on Equity high stood at 0.66% for Q4 2019, and its period low was -0.44% during Q3 2021.
  • For the 3-year period, Black Diamond Therapeutics' Return on Equity averaged around -0.03%, with its median value being -0.19% (2020).
  • Data for Black Diamond Therapeutics' Return on Equity shows a maximum YoY slumped of 87bps (in 2020) over the last 5 years.
  • Black Diamond Therapeutics' Return on Equity (Quarterly) stood at 0.66% in 2019, then crashed by 87bps to -0.21% in 2020, then decreased by 28bps to -0.44% in 2021.
  • Its last three reported values are -0.44% in Q3 2021, -0.31% for Q2 2021, and -0.21% during Q4 2020.